Search

Search Constraints

You searched for: Author/Creator Bahlo, Jasmin

Search Results

11. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Issue 2 (1st February 2017)

12. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Issue 7 (July 2016)

13. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. (22nd January 2022)

14. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Issue 10 (October 2017)

15. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Issue 1 (February 2020)

16. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Issue 3 (3rd March 2016)

17. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance. Issue 3 (23rd February 2019)

18. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Issue 2 (9th October 2017)

19. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. (21st November 2018)

20. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Issue 8 (August 2013)